Patents by Inventor Leticia NIBORSKI

Leticia NIBORSKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immune cells defective for SUV39H1
    Patent number: 11622978
    Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
    Type: Grant
    Filed: January 20, 2020
    Date of Patent: April 11, 2023
    Assignees: INSTITUT CURIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Sebastian Amigorena, Eliane Piaggio, Christel Goudot, Luigia Pace, Genevieve Almouzni, Leticia Niborski
  • Immune cells defective for Suv39h1
    Patent number: 11285176
    Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
    Type: Grant
    Filed: October 21, 2021
    Date of Patent: March 29, 2022
    Assignees: INSTITUT CURIE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Sebastian Amigorena, Eliane Piaggio, Christel Goudot, Luigia Pace, Genevieve Almouzni, Leticia Niborski
  • INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY
    Publication number: 20200157225
    Abstract: The present invention relates to an inhibitor of H3K9 histone methyl transferase SUV39H1 for use in combination with at least one immune checkpoint modulator in the treatment of cancer.
    Type: Application
    Filed: January 27, 2020
    Publication date: May 21, 2020
    Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Leticia NIBORSKI
  • INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY
    Publication number: 20200147099
    Abstract: The present invention relates to an inhibitor of H3K9 histone methyl transferase SUV39H1 for use in combination with at least one immune checkpoint modulator in the treatment of cancer.
    Type: Application
    Filed: June 20, 2018
    Publication date: May 14, 2020
    Inventors: Sebastian AMIGORENA, Eliane PIAGGIO, Leticia NIBORSKI